Various governmental regulatory and oversight organisations continue to scrutinise pharmaceutical companies' government price reporting practices. Government investigations have led to negotiations and settlements with the Office of the Inspector General (OIG), requiring several pharmaceutical manufacturers to comply with the terms and conditions of a Corporate Integrity Agreement (CIA). CIAs, which can last from five to eight years, are costly, consume internal resources and are challenging to implement.
PwC provides comprehensive government-price-reporting compliance services that assess the policies, procedures and systems which support the submission of pricing information to federal and state agencies. We understand the complexity surrounding the pharmaceutical industry's underlying sales and marketing information systems, promotional and discounting programmes, and the issues that arise when applying them to complex and, at times, unclear government reporting requirements.